Myeloma Multiple Clinical Trial
Official title:
Evaluation of a Range of Dermo-cosmetic Products to Treat Skin and Nail Toxicity Linked to Bispecific Anti-GPRC5D Bispecific Antibodies in Multiple Myeloma Patients". Myeloma.
The aim of this study is to assess the efficacy of range of dermo-cosmetic products (hand/feet serum, nail strengthening solution nail strengthening solution, dissolving oil and gloves/slippers) based on natural products and designed for cancer patients)on bispecific Ac-induced skin and nail toxicity in MM patients treated with anti-CD3xGPRC5D bispecific antibodies. The effects of supportive care products will be studied as a preventive measure in patients starting treatment with bispecific Ac and as a curative measure in patients undergoing treatment. Patients will be able to apply the products directly at home according to the study schedule, and a skin and nail toxicity skin and nail toxicity will be performed each time the patient comes for administration of bispecific Ac. Follow-up will be for a total of 6 months (or less if progression occurs earlier), and patients will be asked to complete a quality-of-life questionnaire at protocol inclusion and after 1 month and 6 months of supportive care.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT06205823 -
Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMM
|
||
| Recruiting |
NCT04782687 -
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
|
Phase 2 | |
| Active, not recruiting |
NCT05889221 -
Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma
|
N/A | |
| Recruiting |
NCT03891914 -
Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma
|
Phase 3 | |
| Not yet recruiting |
NCT05944783 -
Bioequivalence Studies of Dasatinib 100 mg
|
Phase 4 | |
| Recruiting |
NCT04268199 -
A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment
|
Phase 2 | |
| Not yet recruiting |
NCT06133426 -
Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients
|
N/A | |
| Completed |
NCT05887206 -
Corneal Toxicity in Patients Treated by Belantamab Mafodotin
|
||
| Completed |
NCT04065789 -
Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03089411 -
Collection of Additional Data Followed the Study IFM 2013-04
|
N/A | |
| Completed |
NCT04436029 -
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
|
Phase 2 | |
| Not yet recruiting |
NCT04364724 -
CTFEA Myeloma Study
|
||
| Recruiting |
NCT05932680 -
Limited-duration Teclistamab
|
Phase 2 | |
| Completed |
NCT04236063 -
Rehabilitation Needs of the Malaysian Haematological Cancer Survivors
|
||
| Terminated |
NCT04242121 -
The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral Blood
|
||
| Not yet recruiting |
NCT03607643 -
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05651932 -
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
|
Phase 1 | |
| Not yet recruiting |
NCT06245629 -
Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
|
||
| Recruiting |
NCT03992170 -
Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive
|
Phase 2 | |
| Terminated |
NCT04843579 -
Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients
|
Phase 2 |